• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Updates Guidance on Form 1572 Waivers for Foreign Investigators

FDA Updates Guidance on Form 1572 Waivers for Foreign Investigators

May 24, 2021

The FDA has updated its guidance on Form 1572, the FDA’s Statement of Investigator, to clarify what sponsors can or should do if a foreign investigator is unable or unwilling to sign the form.

The guidance was developed in response to sponsor questions on how to proceed if regional, national or local laws or regulations prohibit a foreign investigator from signing the form. One option is to request a waiver from the FDA. Another is to have the foreign site operate as a noninvestigational new drug (IND) site.

The FDA also recommended that sponsors obtain signed, written statements from investigators acknowledging their commitment to comply with any applicable regional, national or local laws.

For sponsors that choose to conduct a foreign clinical study or to operate non-U.S. sites in a multinational study under an IND, the FDA says the foreign investigators would still be in compliance with U.S. regulations if they follow International Council for Harmonization (ICH) E6 Good Clinical Practice guidelines, with two exceptions:

  • FDA requirements for IRBs differ slightly under ICH E6, so sponsors would need to request an additional waiver; and
  • Informed consent requirements for IRBs are more extensive under ICH E6 than under FDA regulations.

Comments on the draft guidance are due by July 19.

Read the FDA guidance here: https://bit.ly/3u79ICC.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing